Introduction
Pharmaceutical formulation scientists face a persistent challenge in improving drug solubility, with over 70% of new chemical entities and nearly 40% of marketed drugs exhibiting low aqueous solubility. Traditional techniques like micronization often fail to achieve the necessary particle size for complex molecules. Nanomilling, which reduces particles to the 100–200 nanometer range, significantly increases surface area, enhancing dissolution rates and bioavailability.
The Science Behind Nanomilling
The scientific principle driving this approach is grounded in the Noyes-Whitney equation, which states that dissolution rate is directly proportional to the surface area of the drug particles. By reducing particle size from the micron scale (typically 1–10 μm) down to the nanoscale (100–200 nm), the total surface area increases exponentially—not linearly. Consider the dramatic difference:
- A 10 μm particle reduced to 100 nm generates approximately 1,000 times more individual particles
- This creates a corresponding exponential increase in total surface area
- Traditional micronization may double or triple surface area at best
- Nanomilling can increase surface area by orders of magnitude
This fundamental relationship explains why traditional micronization often falls short for poorly soluble drugs classified as BCS Class II or IV. Nanomilling accelerates dissolution rates sufficiently to achieve clinically meaningful improvements in drug absorption, often transforming a failed development candidate into a viable product.
Comparison Table
When formulation teams evaluate strategies to improve bioavailability, they typically consider several options: lipid-based formulations, liposomes, nanoemulsions, spray-dried dispersions, and nanomilling. Each has its place, but nanomilling offers a unique combination of attributes that make it particularly attractive for challenging drug candidates. The table below summarizes key differentiators:
| Parameter | Liposomes | Nanoemulsions | Spray-Dried Dispersions | Nanomilling |
| Typical API Load | Low (<5%) | Moderate (5–15%) | Moderate (10–30%) | High (5–40+%) |
| Organic Solvents Required | Yes | Sometimes | Yes | No (water-based) |
| Scalability | Challenging | Moderate | Complex | Proven commercial scale |
| Batch-to-Batch Reproducibility | Variable | Moderate | Process-dependent | High (optimized) |
| Physical Stability Risk | Aggregation | Coalescence | Recrystallization | Low (steric stabilization) |
As the table illustrates, nanomilling to prepare small particle size drug particles services provide the rare combination of high drug loading, solvent-free processing, and straightforward scale-up. These advantages become decisive factors in technology selection for:
- Programs targeting chronic indications where high daily doses are required
- Pediatric formulations where taste masking and dose flexibility are paramount
- Parenteral products requiring sterile, stable nanosuspensions
Workflow – The Five Stages of Nanomilling
Understanding the technical workflow is essential for formulation scientists evaluating whether nanomilling is appropriate for their specific drug candidate. A typical nanomilling engagement proceeds through five disciplined stages:
- Establish target product profile – Screen the API against GRAS-approved excipients (stabilizers, surfactants, and viscosity modifiers) to identify a compatible formulation matrix.
- Perform wet media milling – Conduct under controlled conditions (often aseptic for parenteral applications) using specialized equipment that circulates the API suspension through a chamber containing small milling beads.
- Characterize particle size distribution – Use dynamic light scattering or laser diffraction to confirm a mean particle size in the 100–200 nm range.
- Generate short-term stability data – Assess aggregation risk and confirm that the nanosuspension remains physically stable under intended storage conditions.
- Scale promising formulations – Provide material for animal pharmacokinetic studies, generating the proof-of-concept data needed to advance the program.
Once a stable nanosuspension is achieved, it can be further processed into various oral solid dosage forms—including granules, capsules, or tablets—depending on the target product profile.
Providers of comprehensive nanomilling to prepare small particle size drug particles services will include all these steps as part of an integrated offering, reducing the need for multiple vendor handoffs.
Scale-Up Considerations
One of the most common concerns voiced by formulation scientists evaluating nanomilling is whether a process that succeeds at the laboratory scale will translate reliably to commercial manufacturing. This concern is legitimate; many solubilization technologies—liposomes and certain nanoemulsions, in particular—exhibit significant variability when production volumes increase. Nanomilling, however, has a distinct advantage in this regard.
Why nanomilling scales effectively:
Commercial equipment uses a recirculating process design – the API suspension passes repeatedly through the milling chamber until the target particle size is achieved
The fundamental mechanism of particle size reduction does not change with batch size
Key process variables remain constant across scales:
Milling bead size
Chamber speed
Residence time
Temperature
Batch size is increased simply by running the recirculating loop longer or using larger-capacity holding vessels
This linear scalability has been validated across numerous approved drug products, making nanomilling one of the few nanoparticle technologies with a proven regulatory track record for commercial-scale production.
Case Example – When Nanomilling Is the Right Choice
Consider a hypothetical but representative scenario: a development program for an antifungal drug candidate belonging to BCS Class II exhibits less than 5% oral bioavailability in preclinical models due to extremely poor aqueous solubility (approximately 2 μg/mL).
The challenge:
- Traditional micronization achieves a mean particle size of 3 μm
- Bioavailability improves only marginally to 8%
- The candidate remains below efficacy thresholds
The nanomilling solution:
- Optimized process yields a mean particle size of 120 nm with narrow distribution
- Nanosuspension is then converted into oral granules via wet granulation or lyophilization
Results in preclinical models:
4-fold increase in Cmax
3-fold increase in AUC
Exposure reaches levels consistently associated with efficacy
This example illustrates how nanomilling to prepare small particle size drug particles services can transform a marginal candidate into a viable development asset.
Selecting a Provider – Key Criteria + Primary Backlink
Not all providers of nanomilling services operate at the same level of capability. When evaluating potential partners for your program, several criteria merit close attention:
Aseptic processing capabilities – Required if your intended route of administration demands sterility (e.g., parenteral products)
Analytical toolkit – Does the provider have in-house capabilities for:
- Dynamic light scattering
- Laser diffraction
- Zeta potential measurement
- Short-term stability testing
Scale-up experience – Has the provider successfully transferred nanomilling processes from lab-scale to clinical or commercial batches?
Regulatory track record – Experience with IND-enabling studies or approved products is a meaningful differentiator
Companies offering comprehensive nanomilling to prepare small particle size drug particles services should meet all these criteria.
Many providers also offer integrated formulation services to convert nanomilled APIs into finished dosage forms such as granules, capsules, or tablets—enabling a seamless path from particle size reduction to final drug product.
CD Formulation’s nanomilling platform is one example of a provider with:
- Sterile processing capabilities
- A complete analytical suite
- Commercial-scale equipment designed for seamless technology transfer
- Complementary granules development services (available upon request)
Conclusion
As the pharmaceutical industry pursues increasingly complex molecular targets, poor solubility will remain a critical bottleneck. Nanomilling has proven itself as a scalable, reproducible, and commercially viable solution.
The bottom line: For BCS Class II or IV compounds struggling to achieve meaningful bioavailability, nanomilling to prepare small particle size drug particles services offers a practical, low-risk path forward. Whether advancing a new chemical entity or reformulating an existing product, nanomilling belongs in every formulation scientist’s toolkit.
